<?xml version='1.0' encoding='utf-8'?>
<document id="25242374"><sentence text="Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer."><entity charOffset="29-46" id="DDI-PubMed.25242374.s1.e0" text="eribulin mesylate" /></sentence><sentence text="Eribulin mesylate (HalavenÂ®) is a novel inhibitor of microtubule dynamics that has demonstrated a survival benefit in patients with locally recurrent or metastatic breast cancer who previously received at least two chemotherapeutic regimens including an anthracycline and a taxane"><entity charOffset="0-17" id="DDI-PubMed.25242374.s2.e0" text="Eribulin mesylate" /><entity charOffset="19-26" id="DDI-PubMed.25242374.s2.e1" text="Halaven" /><entity charOffset="254-267" id="DDI-PubMed.25242374.s2.e2" text="anthracycline" /><entity charOffset="274-280" id="DDI-PubMed.25242374.s2.e3" text="taxane" /><pair ddi="false" e1="DDI-PubMed.25242374.s2.e0" e2="DDI-PubMed.25242374.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25242374.s2.e0" e2="DDI-PubMed.25242374.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25242374.s2.e0" e2="DDI-PubMed.25242374.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25242374.s2.e0" e2="DDI-PubMed.25242374.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25242374.s2.e1" e2="DDI-PubMed.25242374.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25242374.s2.e1" e2="DDI-PubMed.25242374.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25242374.s2.e1" e2="DDI-PubMed.25242374.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25242374.s2.e2" e2="DDI-PubMed.25242374.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25242374.s2.e2" e2="DDI-PubMed.25242374.s2.e3" /></sentence><sentence text=" Although trastuzumab is indicated for patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, a phase 1 study to evaluate tolerability/safety of eribulin mesylate with trastuzumab has not been conducted"><entity charOffset="177-194" id="DDI-PubMed.25242374.s3.e0" text="eribulin mesylate" /></sentence><sentence text=" Therefore, a study of eribulin mesylate in combination with trastuzumab was conducted to evaluate dose limiting toxicity (DLT), tolerability/safety, pharmacokinetics (PK), and efficacy and to estimate the recommended dose in Japanese patients with advanced or recurrent HER2+ breast cancer"><entity charOffset="23-40" id="DDI-PubMed.25242374.s4.e0" text="eribulin mesylate" /></sentence><sentence text=" Eribulin mesylate (1"><entity charOffset="1-18" id="DDI-PubMed.25242374.s5.e0" text="Eribulin mesylate" /></sentence><sentence text="4 mg/m(2)) was administered on days 1 and 8 of every 3 week cycle" /><sentence text=" Trastuzumab was administered with a 4 mg/kg loading dose followed by 2 mg/kg weekly doses or with an 8 mg/kg loading dose followed by 6 mg/kg tri-weekly doses" /><sentence text=" A total of 12 patients (six for each regimen) received eribulin mesylate and trastuzumab"><entity charOffset="56-73" id="DDI-PubMed.25242374.s8.e0" text="eribulin mesylate" /></sentence><sentence text=" No DLT was observed and the recommended dose of eribulin mesylate in combination with trastuzumab was estimated as 1"><entity charOffset="49-66" id="DDI-PubMed.25242374.s9.e0" text="eribulin mesylate" /></sentence><sentence text="4 mg/m(2)" /><sentence text=" Common adverse events were neutropenia, leukopenia, anaemia and alopecia" /><sentence text=" This combination therapy was well tolerated and the neutropenia observed was manageable" /><sentence text=" No PK drug-drug interaction between eribulin and trastuzumab was observed"><entity charOffset="37-45" id="DDI-PubMed.25242374.s13.e0" text="eribulin" /></sentence><sentence text=" Since a transient ejection fraction decreased was observed in two patients, cardiac function should be routinely assessed in patients receiving the combination therapy of eribulin mesylate with trastuzumab (ClinicalTrials"><entity charOffset="172-189" id="DDI-PubMed.25242374.s14.e0" text="eribulin mesylate" /></sentence><sentence text="gov Identifier: NCT01432886)" /><sentence text="" /></document>